Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )

Documenti analoghi

• Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
  di: Scott A. Coon, et al.
  Pubblicazione: (2025)
• Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study
  di: Michael G. Nanna, et al.
  Pubblicazione: (2026)
• Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
  di: Testimony Ipaye, et al.
  Pubblicazione: (2025)
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
  di: Michelle Look, et al.
  Pubblicazione: (2025)
• Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
  di: Chih‐Yuan Wang
  Pubblicazione: (2026)